Last reviewed · How we verify
AMDX-2011P
AMDX-2011P is a small molecule that targets the SGLT2 receptor.
AMDX-2011P is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AMDX-2011P |
|---|---|
| Sponsor | Amydis Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, AMDX-2011P reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of how AMDX-2011P interacts with the SGLT2 receptor are not well understood.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Study of AMDX-2011P in Participants With Alzheimer's Disease (PHASE2)
- A Study of AMDX-2011P in Participants With CAA (PHASE2)
- Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy (PHASE1, PHASE2)
- A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMDX-2011P CI brief — competitive landscape report
- AMDX-2011P updates RSS · CI watch RSS
- Amydis Inc. portfolio CI